Lucid Diagnostics Inc (LUCD) - Total Liabilities
Based on the latest financial reports, Lucid Diagnostics Inc (LUCD) has total liabilities worth $27.36 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Lucid Diagnostics Inc to assess how effectively this company generates cash.
Lucid Diagnostics Inc - Total Liabilities Trend (2018–2024)
This chart illustrates how Lucid Diagnostics Inc's total liabilities have evolved over time, based on quarterly financial data. Check Lucid Diagnostics Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Lucid Diagnostics Inc Competitors by Total Liabilities
The table below lists competitors of Lucid Diagnostics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Empro Group Inc. Ordinary shares
NASDAQ:EMPG
|
USA | $3.06 Million |
|
Den Networks Limited
NSE:DEN
|
India | Rs5.09 Billion |
|
Sarana Mitra Luas
JK:SMIL
|
Indonesia | Rp405.85 Billion |
|
Pulse Seismic Inc
TO:PSD
|
Canada | CA$6.16 Million |
|
Betmakers Technology Group Ltd
AU:BET
|
Australia | AU$39.22 Million |
|
Cashbil
JSE:CSB
|
South Africa | ZAC5.34 Billion |
Liability Composition Analysis (2018–2024)
This chart breaks down Lucid Diagnostics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Lucid Diagnostics Inc market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.90 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lucid Diagnostics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lucid Diagnostics Inc (2018–2024)
The table below shows the annual total liabilities of Lucid Diagnostics Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $25.32 Million | -14.39% |
| 2023-12-31 | $29.58 Million | +212.63% |
| 2022-12-31 | $9.46 Million | +122.11% |
| 2021-12-31 | $4.26 Million | -72.89% |
| 2020-12-31 | $15.71 Million | +147.71% |
| 2019-12-31 | $6.34 Million | +487.07% |
| 2018-12-31 | $1.08 Million | -- |
About Lucid Diagnostics Inc
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the… Read more